Every article, report, and earnings note where INSM appears.
Insmed is transitioning from cash-burning biotech to a commercial respiratory growth story, powered by BRINSUPRI’s rapid launch and improving margins. The stock looks attractive on execution, but valuation already reflects meaningful success.
Insmed Incorporated (INSM) spikes in extended-hours trading after its second-quarter 2026 earnings and business update. Investors are reacting to BRINSUPRI’s commercial momentum, analyst support, and the company’s push toward at least $1 billion in 2026 revenue.
Insmed Incorporated (INSM) climbs sharply as investors continue to digest its strong Q1 update, including rapid BRINSUPRI growth, steady ARIKAYCE sales, and encouraging ENCORE data. The move reflects renewed confidence in the company’s 2026 revenue targets and its expanding commercial and pipeline story.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate INSM ReportCancel anytime